Creo Medical Group PLC (CREO) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Creo Medical Group PLC £0.15, price £0.12, upside +24.9%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Creo Medical Group PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range £0.0955 – £2.05 · fair‑value band £0.1190 – £0.1955 · the £0.1225 price screens below the £0.1530 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Creo Medical Group in your weekly email
Every Wednesday you see whether Creo Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom.
Show more
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
Stock analysis
Creo Medical Group PLC (CREO) currently trades at £0.1225, while our model-based Fair Value estimate is £0.1530, implying the stock looks roughly 19.9% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of £0.5100 per share, and 6 of the 9 models we run sit above the £0.1225 price.
Bear case: the Asset-Based group reads lowest at £0.0700, and 3 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: £0.1190 (bear) to £0.1955 (bull), the price of £0.1225 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Creo Medical Group PLC reported revenue of £6.0M in FY2025 versus £25.2M in FY2021, a compound −30.1%/yr. Reported net income was £5.3M in FY2025.
Key figures
Market cap 69.2M GBX · EPS (TTM) £−0.0400 · Net margin 88.3% · Return on equity −76.5% · Return on assets (EBIT) −36.5% · Operating margin −4,571% · Revenue growth (YoY) +37.5% · Free cash flow −18.6M GBX.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 25%, CREO screens cheaper than that median.
Fair Value models
Bear £0.1190Fair Value £0.1530Bull £0.1955
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.9/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic)
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
’14
’16
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−248.1% (2020) → −345.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside+25% · Top 25%
Profitability
Return on assets−50% · Bottom 25%
Net margin (TTM)88% · Top 25%
Growth and dividend
Revenue growth38% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Creo Medical Group PLC Fair Value". https://www.fairvalue-calculator.com/stock/CREO
Frequently asked questions
Is Creo Medical Group PLC (CREO) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of £0.1530 versus a price of £0.1225, about +25% upside (undervalued).
What is the fair value of CREO?
Our model-based fair value for Creo Medical Group PLC is £0.1530 (as of Sep 23, 2026), built from audited fundamentals. The current price: £0.1225.
What is the quality score of CREO?
Creo Medical Group PLC has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Creo Medical Group PLC (CREO)?
Our model-based price target is the fair value of £0.1530 (as of Sep 23, 2026) from 9 valuation models. Cautious scenario £0.1190, optimistic scenario £0.1955. It is a calculation from audited fundamentals, not an analyst target.
What is the Creo Medical Group PLC stock forecast for 2026?
Our models put fair value at £0.1530, about +25% upside versus a price of £0.1225 (undervalued). Cautious scenario £0.1190, optimistic scenario £0.1955. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Creo Medical Group PLC (CREO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Creo Medical Group PLC it is £0.1530 per share (as of Sep 23, 2026), against a price of £0.1225. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Creo Medical Group PLC stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CREO trades below its calculated fair value: price £0.1225, fair value £0.1530, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CREO?
No. The price is what the market pays today (£0.1225); the fair value is what the company's own numbers justify (£0.1530). For Creo Medical Group PLC the two are £0.0305 per share apart. That gap is exactly why we show both numbers side by side.
How much is Creo Medical Group PLC worth?
The market values Creo Medical Group PLC at about 69.2M GBX (market capitalisation, as of Sep 23, 2026). Per share that is £0.1225; our models calculate a fair value of £0.1530 per share.
What do the bullish and bearish scenarios say about CREO?
Our models span a range for Creo Medical Group PLC: cautious scenario £0.1190, base £0.1530, optimistic £0.1955 per share (as of Sep 23, 2026, price £0.1225). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Creo Medical Group PLC (CREO)?
Balance-sheet figures for Creo Medical Group PLC (as of Sep 23, 2026): return on equity −76.5%, debt of 0.04 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is CREO from its 52-week high?
Creo Medical Group PLC trades at £0.1225, about 31% below its 52-week high of £0.1775 and 24% above the low of £0.0990 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.1530 is for.
Which stocks are comparable to Creo Medical Group PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Creo Medical Group PLC stock attractive at the current price?
The data as of Sep 23, 2026: price £0.1225, calculated fair value £0.1530 (+25%), Quality Score 48/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CREO calculated?
We run Creo Medical Group PLC through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.1530, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Creo Medical Group PLC currently trades 25 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Creo Medical Group PLC (CREO)?
The closing price on Sep 24, 2026 was £0.1225. Our model-based fair value is £0.1530, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Creo Medical Group PLC right now?
Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Creo Medical Group PLC
How large is the market capitalisation of Creo Medical Group PLC (CREO)?
The market capitalisation of Creo Medical Group PLC is 69.2M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Creo Medical Group PLC (CREO)?
Earnings per share at Creo Medical Group PLC are £−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Creo Medical Group PLC (CREO)?
The net margin of Creo Medical Group PLC is 88.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Creo Medical Group PLC (CREO)?
The return on equity (ROE) of Creo Medical Group PLC is −76.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Creo Medical Group PLC (CREO)?
On an EBIT basis the return on assets of Creo Medical Group PLC is −36.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Creo Medical Group PLC (CREO)?
The operating margin of Creo Medical Group PLC is −4,571% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Creo Medical Group PLC (CREO)?
Revenue at Creo Medical Group PLC is growing +37.5% versus a year earlier (3y avg −39.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Creo Medical Group PLC (CREO) generate?
The free cash flow of Creo Medical Group PLC is −18.6M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Creo Medical Group PLC (CREO) hold?
Creo Medical Group PLC holds more cash than debt, 8.3M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Creo Medical Group PLC in the live analysis
One click puts Creo Medical Group PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026